GLP-1 HEALTH OUTCOMES · TIMELINE
GLP-1 Guideline and Approval Evolution: 2005 to 2026
The GLP-1 field evolved from glucose-lowering therapy into a broader evidence landscape spanning chronic weight management, cardiovascular outcomes, chronic kidney disease, heart failure, MASH and integrated cardiovascular-kidney-metabolic care. This timeline separates regulatory approvals, pivotal trial milestones and guideline adoption.
Explore a research discussion about GLP-1 Guideline and Approval Evolution: 2005 to 2026
Contact the research director about evidence analysis, data questions or an associated professional project.
Research timeline
How GLP-1 therapy moved from glycemic control to multiorgan outcomes
Three evidence lanes
| Evidence lane | What it means | Why it must stay separate |
|---|---|---|
| Regulatory approval | A regulator authorizes a defined use for a specific product and population. | Approval language is narrower than general scientific discussion. |
| Pivotal trial publication | A clinical trial reports results in a defined population and endpoint structure. | A positive trial does not automatically equal an approved indication. |
| Guideline adoption | A professional guideline incorporates evidence into recommendations for clinical practice. | Guidelines may integrate multiple therapies and populations. |
2005: the modern GLP-1 medicine era begins
Exenatide became the first GLP-1 receptor agonist approved in the United States for type 2 diabetes. At this stage, the primary clinical identity of the class was glycemic control. Cardiovascular, kidney and obesity outcomes were not yet the defining public narrative.
This starting point matters because later developments should not be projected backward. Cardiovascular and multiorgan roles emerged through later medicines, doses, formulations, trials and regulatory actions.
2014: obesity becomes a formal treatment indication
Liraglutide's chronic weight-management approval marked an important expansion beyond type 2 diabetes. It helped establish the idea that incretin-based therapy could address body weight as a primary treatment goal rather than only as a secondary metabolic effect.
The milestone also reinforced the regulatory distinction between diabetes-oriented and obesity-oriented products, doses and brand claims.
2016 to 2018: cardiovascular outcomes reshape the field
Major cardiovascular-outcomes trials such as LEADER and SUSTAIN-6 showed that selected GLP-1 receptor agonists could reduce major cardiovascular events in high-risk people with type 2 diabetes. Cardiovascular event reduction became a central evidence domain rather than a secondary research question.
Guidelines subsequently incorporated GLP-1 receptor agonists with demonstrated cardiovascular benefit into risk-reduction strategies for selected people with type 2 diabetes and cardiovascular disease or high cardiovascular risk.
2021: Wegovy accelerates the obesity-treatment era
Semaglutide 2.4 mg for chronic weight management substantially increased clinical and public attention to GLP-1 therapy for obesity. The STEP program also changed expectations about the magnitude of pharmacologic weight loss achievable in many patients.
2022 to 2023: tirzepatide expands incretin biology
Tirzepatide introduced dual GIP and GLP-1 receptor agonism into routine clinical practice, with U.S. approvals first for type 2 diabetes and then for chronic weight management. It is often discussed alongside GLP-1 medicines because it includes GLP-1 receptor activity, but it is not a conventional single-receptor GLP-1 agonist.
2023 to 2024: SELECT extends cardiovascular evidence beyond diabetes
SELECT studied adults with established cardiovascular disease and overweight or obesity who did not have diabetes. Semaglutide 2.4 mg reduced the primary three-component MACE endpoint compared with placebo.
In March 2024, FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and either overweight or obesity. FDA: Wegovy cardiovascular indication.
Track the difference between evidence and indication
SELECT, FLOW, STEP-HFpEF and SUMMIT each answer different clinical questions. The outcomes hub keeps trial populations and regulatory claims separated.
2024: kidney and HFpEF evidence becomes harder to ignore
FLOW reported dedicated kidney-outcome evidence for semaglutide in adults with type 2 diabetes and chronic kidney disease, moving beyond earlier kidney-related secondary analyses. In parallel, STEP-HFpEF and STEP-HFpEF DM showed improvements in symptoms, physical limitations, exercise function and body weight in obesity-related HFpEF, while SUMMIT later added tirzepatide evidence involving cardiovascular death or worsening heart-failure events as a primary composite.
2025: Ozempic gains a CKD risk-reduction indication
In 2025, U.S. Ozempic labeling expanded to include reduction in the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This regulatory milestone reflects the FLOW evidence base.
The indication remains population-specific and should not be generalized to every form of CKD. FDA: Ozempic 2025 prescribing information.
2025: Wegovy adds MASH to the evidence map
In August 2025, FDA approved Wegovy for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate-to-advanced fibrosis. This indication was granted under accelerated approval based on histologic improvement and remains subject to verification of clinical benefit in a confirmatory trial.
That evidence standard should not be treated as equivalent to proven reductions in liver-related mortality or transplantation. FDA: Wegovy MASH approval.
2026: CKM becomes an integrated guideline framework
On 9 June 2026, the American Heart Association, American College of Cardiology, American Diabetes Association and American Society of Nephrology published the first multisociety guideline for cardiovascular-kidney-metabolic syndrome. The guideline formalized a staged approach linking obesity, type 2 diabetes, CKD and cardiovascular disease.
The framework incorporates PREVENT risk assessment and GLP-1-based therapy in selected CKM settings while preserving major roles for RAS inhibition, SGLT2 inhibitors and standard heart-failure treatment where indicated. AHA: 2026 CKM guideline.
Three-lane GLP-1 timeline
| Period | Regulatory lane | Trial/evidence lane | Guideline lane |
|---|---|---|---|
| 2005 | First U.S. GLP-1 RA approval for T2D | Early glucose-lowering era | Diabetes-focused use |
| 2014 | Liraglutide obesity indication | Weight-management evidence matures | Obesity pharmacotherapy becomes more relevant |
| 2016–2018 | Cardiovascular claims expand for selected products | LEADER, SUSTAIN-6 and related CVOTs | GLP-1 RAs with proven CV benefit enter T2D cardiovascular-risk recommendations |
| 2021 | Wegovy chronic weight-management approval | STEP obesity program | Modern pharmacologic obesity era accelerates |
| 2022–2023 | Tirzepatide approvals for T2D and chronic weight management | SURPASS/SURMOUNT era | Dual incretin therapy becomes clinically prominent |
| 2024 | Wegovy cardiovascular risk-reduction indication | SELECT, FLOW, STEP-HFpEF and SUMMIT-era evidence | Cardiovascular, kidney and HFpEF roles broaden |
| 2025 | Ozempic CKD indication; Wegovy MASH indication | Dedicated kidney outcomes and liver histology evidence influence labeling | Multiorgan use becomes increasingly explicit |
| 2026 | Current labels span multiple outcome domains | Evidence continues across CKM phenotypes | First AHA/ACC/ADA/ASN CKM guideline integrates cardiovascular, kidney and metabolic management |
How the clinical role changed
Phase 1: Glycemia
The earliest GLP-1 medicines were primarily understood as glucose-lowering therapies for type 2 diabetes.
Phase 2: Weight
Obesity indications made body-weight management a primary therapeutic objective.
Phase 3: Cardiovascular outcomes
CVOTs and SELECT established cardiovascular event reduction in defined populations.
Phase 4: Multiorgan outcomes
Kidney, HFpEF, liver and CKM evidence expanded the field beyond glucose and weight alone.
Why this is not a class-wide approval history
Each milestone belongs to a specific medicine, formulation, dose, population and jurisdiction. A regulatory approval for Wegovy is not automatically an approval for Ozempic, even though both contain semaglutide. A tirzepatide trial is not a semaglutide trial. A guideline can refer to a broader treatment category while still requiring drug-specific evidence.
Approval, trial and guideline language are not interchangeable
A regulator determines whether a specific product can be marketed for a defined indication. A randomized trial estimates outcomes under a defined protocol. A guideline committee integrates multiple evidence sources into recommendations. These processes may align, but they should never be collapsed into one claim.
Population Boundary Box
Approval milestone
Specific product, population, indication and jurisdiction.
Trial milestone
Defined population, intervention, comparator and endpoint structure.
Guideline milestone
Evidence translated into recommendations across a clinical framework.
Do not infer
That one product's approval or one trial's outcome automatically applies to the whole class.
Key timeline sources
- FDA: 2024 Wegovy cardiovascular indication
- FDA: 2025 Ozempic prescribing information including CKD indication
- FDA: 2025 Wegovy MASH approval
- AHA: 2026 CKM guideline
- JACC: 2026 AHA/ACC/ADA/ASN CKM guideline
Explore the outcomes behind the timeline
Move from chronology to the cardiovascular, kidney, HFpEF and CKM evidence that changed GLP-1 clinical positioning.
Turn GLP-1 Guideline and Approval Evolution: 2005 to 2026 into an evidence-led discussion
Discuss source interpretation, comparative research, data projects or strategy requirements.
Video explainer
Connected research and evidence context
This video is part of the required connected research layer for the current GLP1Scientist outcomes batch.
Frequently asked questions
Questions about GLP-1 approvals and guideline evolution
When did GLP-1 medicines first become available?
The modern GLP-1 medicine era began in 2005 with U.S. approval of exenatide for type 2 diabetes.
When did GLP-1 therapy move beyond diabetes?
A major regulatory step was the 2014 liraglutide obesity indication, followed by later cardiovascular, kidney and other outcome-focused expansions.
What changed in 2026?
The first multisociety CKM guideline integrated cardiovascular, kidney and metabolic disease into a staged framework and included GLP-1-based therapy in selected CKM settings.
Are trial and approval dates interchangeable?
No. Trial publication, regulatory approval and guideline adoption are separate milestones and should be reported separately.
Connected ecosystem
Broader research, innovation and professional resources
Explore related technology, business, patent, legal and global research platforms connected with the wider research ecosystem.
Research direction
Research direction by Dr. Rahul Dev
GLP1Scientist treats GLP-1 history as three linked but separate trajectories: regulatory approvals, pivotal outcome evidence and guideline adoption. This prevents a trial result from being presented as an approval and prevents a guideline recommendation from being generalized beyond its defined population.
Future revisions should add only milestones that materially change clinical positioning, regulatory scope or evidence interpretation.
Continue your research
Continue through the GLP-1 evidence map
GLP-1 HEALTH OUTCOMES
Explore the complete outcomes cluster
Move between the master hub, organ-specific evidence, pivotal trials and the guideline timeline.
GLP1Scientist video overview
This video offers additional platform context. Medical and regulatory claims should be checked against the cited primary sources and current official information.